Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh firm rides ...

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

This is an audio transcript of the FT News Briefing podcast episode: ‘Big Pharma markets left in a ‘patent cliff’-hanger’ ...

U.S. appetite for U.K. companies is only intestifying in 2025; here, Law.com charts some of the highest profile deals in H1, ...

For the third time in four years, CNBC has ranked North Carolina as “America’s Top State for Business” in 2025.

US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...